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Tools for Zebraﬁsh Research
This Program Announcement (PA) is to encourage
investigator-initiated applications designed to exploit the
power of the zebraﬁsh as a vertebrate model for bio-
medical and behavior research. Applications proposing
to develop new tools or genetic or genomic resources of
high priority to the zebrafish community that will
advance the detection and characterization of genes,
pathways, and phenotypes of interest in development
and aging, organ formation, behavior, and disease
processes are welcome. This effort stems from an NIH
initiative developed by the Institutes and Centers of the
Trans-NIH Zebrafish Coordinating Committee
(TZCC; http://www.nih.gov/science/models/zebraﬁsh/)
under the co-chairmanship of NICHD and NIDDK.
Since its formation in 1997, the committee has played
an active role as an advocate for the zebrafish as an
important model for development and disease research.
PAR-02-142, “Tools for Genetic Studies in Zebraﬁsh”
(http://grants.nih.gov/grants/guide/pa-ﬁles/PAR-02-
142.html) was issued in August 2002 because it was
clear that there was a critical need for non-hypothesis
driven, tool development proposals to be reviewed as a
group, within a single framework. It focused on identi-
fying additional mutants and developing new genetic
tools in zebraﬁsh. Ongoing dialog with the zebraﬁsh
research community, most recently at the Sixth
International Meeting on Zebraﬁsh Development and
Genetics in June 2004, suggested a continuing need
for not only tools, but high priority resources as well.
Therefore, this PA is a continuation of the program
initiated by PAR-02-142. The objective is to continue
to broaden the range, power, and utility of tools for
biomedical and behavioral research using zebrafish,
and to develop genetic and genomic resources of high
priority to the zebrafish community. Methodology
developed and data and mutants generated as a result
of this PA are expected to be made widely available to
the research community as described by NIH Grants
Policy (Principles and Guidelines for Recipients of
NIH Research Grants and contracts on Obtaining
and Disseminating Biomedical Research Resources:
Final Notice, December 1999, http://ott.od.nih.gov/
NewPages/Rtguide_final.html and the NIH Model
Organism Sharing Policy, http://grants.nih.gov/grants/
policy/model_organism/index.htm).
Objectives to be addressed in applications submit-
ted in response to this PA include, but are not limited
to, the following: 1) development and/or application of
novel methods of mutagenesis (e.g., insertional, site-
specific, conditional knockout vectors or systems);
2) development of techniques supporting more efﬁcient
targeting of induced local lesions in genomes (TILL-
ING); 3) development of technologies for gene inacti-
vation and for gene expression manipulation including,
but not limited to, morpholino oligonucleotides, new
types of antisense technology, techniques for homolo-
gous recombination, techniques for gene trapping, and
strategies for directing gene misexpression, or other
transgenic methodologies; 4) development of high
throughput small molecule screens; 5) development of
new genetic or genomic resources that are of high prior-
ity for the zebrafish community; 6) development
and/or application of novel screens for mutants; these
may be reﬁnement of phenotypic analyses preparatory
to screening, or phenotypic screens based on observa-
tion of alterations in morphology, physiology, or
behavior; 7) screens focusing on identifying novel
developmental genes; and pathways, including those
mediating sensitivity or resistance to environmental
toxicants; 8) screens to analyze the genetic basis of adult
phenotypes including behavior, aging, organ disease,
cancer, and responses to environmental toxicants,
alcohol, and drugs of abuse.
The participating NIH Institutes and Centers
have provided a brief outline of their interests as they
relate to the goals of this PA. These brief mission
statements are intended to indicate the breadth of
the biomedical areas of interest in which zebrafish
are likely to be a useful model.
NCI: Generation and study of zebraﬁsh models
to identify and place genes in functional pathways
that effect growth and development, in particular,
genes/pathways that, when altered, result in uncon-
trolled or cancerous growth.
NCRR: The NCRR supports research projects
that broaden the utility of the zebrafish model for
cross-cutting biomedical research that is not encom-
passed within a single NIH Institute or Center.
Interests include, but are not limited to, development
of new methods for mutagenesis and/or phenotypic
characterization that would be of use in research on a
wide range of diseases or organs, particularly if these
methods could be applied to other animal models as
well as the zebraﬁsh.
NEI: Research on the normal and abnormal
visual system, including eye development, optic nerve
guidance and the visual centers of the brain. This
research might include the use of mutants to eluci-
date the cellular and molecular processes that control
normal eye development and function and to provide
models for the investigation of the genetic bases of
inherited eye diseases.
NHLBI: Cellular and molecular functions of
zebraﬁsh genes that have potential to model human
cardiovascular, blood, and pulmonary, or sleep dis-
orders. Genetic basis of disorders of cardiovascular
development and function; effect of mutations on sub-
sequent organ development leading to such disorders
as arrhythmia, cardiac hypertrophy, dilated cardio-
myopathy, and heart failure; developmental aspects of
endothelial dysfunction as the basis for vascular dis-
orders; developmental defects in hematopoiesis and the
relationship to disorders of the hematopoietic system;
genetic basis of angiogenesis, and vasculogenesis; and,
the genetic basis, regulation, and role of biological clock
mechanisms in development and circadian behavior.
NIA: Basic research on the genetic and molecular
basis of aging and longevity. Generation and analysis
of late-onset disease models or long-lived mutants that
can be used to identify, clone, and characterize genes
involved in normal and pathological aging. Cellular
and molecular function of genes expressed, for example,
in the aging nervous system, cardiovascular, immune,
and musculoskeletal systems. Such genes include, but
are not limited to, those involved in neurodegenerative
disorders, neuroplasticity, cell death, damage and repair
of DNA and proteins, oxidative stress, and mainte-
nance of differentiated cell function.
NIAAA: Mechanistic studies of ethanol-induced
teratogenesis, behavioral impairments, and organ
damage. These studies may include screening meth-
ods for alcohol-related phenotypes, gene identifica-
tion, and functional analyses of these genes.
NIAMS: Mutations that have the potential to
illuminate the development and function of the ver-
tebrate musculoskeletal system and skin. The muscu-
loskeletal system includes muscle, bone, articulated
joints, cartilage, tendon, and ligament. Priority will
be given to the establishment of collaborations
between investigators with expertise in the zebraﬁsh
and investigators with expertise in the musculoskele-
tal systems and skin of mammals and humans.
NICHD: Identiﬁcation, cloning, and characteri-
zation of the genes important in normal development
as well as those mutant genes that cause developmental
defects. Elucidation of the cellular, biochemical, mole-
cular, and genetic mechanisms underlying normal and
defective development. This includes, but is not lim-
ited to, the study of general mechanisms of pattern for-
mation and cell lineage, neural crest development, cell
specification, differentiation, migration, and fate in
early development of many organs/systems such as
limb, nervous system, immune system, and heart.
NIDCD: Identification and cloning of genes/
proteins involved in the normal and disordered devel-
opment in the areas of hearing, balance, smell, taste,
voice, speech, and language. Elucidation of the cellu-
lar, molecular, and biochemical and sensory processing
mechanisms governing the proliferative, regenerative,
lineage determination, and developmental capacities of
these sensory cells and tissues.
NIDCR: All aspects of normal and abnormal
craniofacial development, including genetics, com-
plex origins of craniofacial disorders, cell lineages and
differentiation, cell signaling and gene regulation,
embryonic patterning, imaging, biomimetics, and
new technologies for high-throughput genetic and
protein screens.
NIDDK: Research on diabetes, particularly
studies on pancreatic beta cell function and develop-
ment, obesity and mechanisms underlying satiety,
other endocrine and metabolic diseases, hematologic
disorders, physiology and diseases of the digestive sys-
tem, liver, kidney, and urinary tract. Studies aiming
to clarify the cellular and molecular events that dic-
tate tissue and organ formation in all these systems
are considered of relevance. In addition, studies that
exploit the zebraﬁsh to model physiological processes
such as renal function, ﬂuid and electrolyte balance,
are relevant to NIDDK. These studies could include,
but need not be limited to, studies to develop cell
lines from any of the tissues or organs of interest,
studies to characterize normal or abnormal function
of tissues or organs of interest, methods to screen and
identify additional mutations in these systems, and
studies to deﬁne the molecular mechanisms that dic-
tate cell-speciﬁc gene expression in relevant cell types.
NIDA: Identiﬁcation of mechanisms underlying
tolerance, sensitization, and addiction to drugs of
abuse such as nicotine, amphetamine, cocaine, opiates,
barbiturates, and hallucinogens. Identification of
genetic suppressors and enhancers of the teratological
effects of drugs of abuse on behavior and the nervous
system. Processes involved in the development of brain
regions and neurotransmitter systems mediating the
hedonic and addictive properties of drugs of abuse.
NIEHS: Studies to examine the mechanism
whereby environmental factors/agents alter any aspect
of development. This includes the screening for
mutants that ameliorate the toxicity of environmental
agents, and the subsequent identiﬁcation and charac-
terization of the genes and pathways involved in their
action. Characterization of the interactions among
genetics, environmental agents, and time during devel-
opment that lead to structural or functional abnor-
malities. Studies to examine the mechanistic pathways
involved in developmental exposure to environmental
agents and subsequent increased susceptibility to
adult onset disease (developmental imprinting).
Development of a mechanistically based model for test-
ing environmental agents for developmental toxicity.
NIGMS: Development of novel methods for
mutagenesis and manipulation of gene expression.
Mutagenesis screens to identify and characterize genes
that control fundamental biological mechanisms such
as those that underlie gene regulation, chromosome
organization and mechanics, cell growth and differen-
tiation, pattern formation, sex determination, mor-
phogenesis, cell cycle control, and behavior. Small
molecule screens for phenotypes that are relevant to
those fundamental biological mechanisms.Fellowships, Grants, & Awards
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NIMH: Investigations that examine molecular,
cellular, and biochemical bases of genetic mutations
affecting neurogenesis, biological rhythms, learning,
memory, and other cognitive functions and behaviors
of the nervous system. These studies include, but are
not limited to, development of screening methods for
such mutations, identification, isolation, mapping,
and functional analyses of the genes underlying
mutations.
NINDS: Research on the development, normal
function, and diseases of the nervous system. This
research might include the use of mutants to under-
stand the mechanisms controlling the following
processes: neurogenesis, nervous system patterning,
cell lineage, cell migration, formation of neural cir-
cuits, programmed cell death, axon pathﬁnding and
regeneration, myelination, and motor and sensory
function. In addition, the utility of mutants as models
for neurodegenerative diseases for use in translational
research, including therapeutic drug screens, func-
tional neuroanatomy of the developing and adult ner-
vous system, and use of optical imaging techniques to
visualize neural activity, is of particular interest. The
areas of interest listed above are not presented in any
order of priority, they are only examples of areas of
research to consider. Applications representing areas
of interest to more than one Institute or Center will
be assigned to multiple Institutes or Centers for fund-
ing consideration. Applicants are encouraged to
propose work in other areas that are related to the
objectives and scope of this PA.
This funding opportunity will use the NIH
Individual Research Project Grant (R01) award mecha-
nism(s). As an applicant, you will be solely responsible
for planning, directing, and executing the proposed
project.
This funding opportunity uses just-in-time con-
cepts. It also uses the modular as well as the non-
modular budget formats (see http://grants.nih.gov/
grants/funding/modular/modular.htm). Specifically,
if you are submitting an application with direct costs
in each year of $250,000 or less, use the modular
budget format described in the PHS 398 application
instructions. Otherwise follow the instructions for
nonmodular research grant applications.
The PHS 398 application instructions are avail-
able at http://grants.nih.gov/grants/funding/phs398/
phs398.html in an interactive format. For further
assistance contact GrantsInfo at 301-435-0714, (tele-
communications for hearing impaired: TTY 301-451-
0088) or by e-mail: GrantsInfo@nih.gov.
Applications must be prepared using the most
current PHS 398 research grant application instruc-
tions and forms. Applications must have a D&B
Data Universal Numbering System (DUNS) number
as the universal identiﬁer when applying for Federal
grants or cooperative agreements. The D&B number
can be obtained by calling 866-705-5711 or through
the web site at http://www.dnb.com/us/. The D&B
number should be entered on line 11 of the face page
of the PHS 398 form.
Letters of intent are requested but not required;
the letter of intent deadline for the latest cycle has
passed. Letters of intent for future cycles are due August
19, 2006, 2007. Applications are due September 19,
2005, 2006, 2007. The complete version is available at
http://grants.nih.gov/grants/guide/pa-files/PAR-05-
080.html.
Contact: Lorette Javois, Center for Devel-
opmental Biology and Perinatal Medicine, National
Institute of Child Health and Human Development,
6100 Executive Boulevard, Room 4B01, MSC 7510,
Bethesda, MD 20892-7510 USA, Rockville, MD
20852 USA (for express/courier service; non-USPS
service) 301-496-5541, fax: 301-480-0303, e-mail:
lj89j@nih.gov. Reference: PAR No. PAR-05-080
Innate Immunity to NIAID Category B Protozoa
This initiative will support basic research to deﬁne the
mechanisms of action by which the innate immune sys-
tem recognizes and responds to the food and water-
borne eukaryotes classified as NIAID Category B
priority protozoan pathogens (Cryptosporidium parvum,
Cyclospora cayetanensis, Giardia lamblia, Entamoeba his-
tolytica, Toxoplasma, and Microsporidia) (http://www2.
niaid.nih.gov/Biodefense/bandc_priority.htm).
The NIH and other agencies in the Department
of Health and Human Services (DHHS) are currently
supporting extramural research to develop new prod-
ucts to protect the public from the health conse-
quences of biological agents that might be used in acts
of terrorism or war. The research supported by this
RFA will contribute to meeting the goals for host
defense described in the NIAID Strategic Plan for
Biodefense, which is located at: http://www2.niaid.
nih.gov/Biodefense/Research/strat_plan.htm, by
increasing our understanding of the mechanisms by
which the innate immune system recognizes, responds
to, and neutralizes the complex defense systems of
protozoan pathogens. The complexity of the inter-
actions between the host innate immune system and
protozoan pathogens requires in-depth knowledge of
innate immunity, mucosal immunity, and protozoan
microbiology/biochemistry.
There is evidence that the innate immune system
recognizes and responds to protozoan parasites. Recent
studies have shown that Toxoplasma gondii stimulates
host cells through TLR2 and TLR4, activates B lym-
phocytes, NK and NKT cells, and stimulates Interferon-
gamma and NO production. In other studies,
Cryptosporidium parvum infection activated both CD4+
and CD8+ gamma/delta T cells, and Giardia species
stimulated the release of several effector molecules,
including defensins, cryptdins, and indolicidin. Utilizing
the NIAID Category B protozoa to better understand
the innate immune response to eukaryotic pathogens
may lead to new broad spectrum immunotherapeutics
and adjuvants for protozoan vaccines.
Eukaryotic pathogens are a serious public health
problem in developing countries. Exposure to pathogens
such as Giardia, Cryptosporidium, and Entamoeba has
been greatly diminished in the U.S. due to effective
regulation of public water supplies and commercial food
processing. Thus, interest in protozoan vaccine develop-
ment has lagged behind that for prokaryotic pathogens.
With the recently increased threat of biowarfare, the
potential for adulteration of U.S. food and water sup-
plies has increased. In-depth understanding of innate
immune responses to protozoa is important because
their genomic complexity affords them a greater variety
of immune evasion mechanisms than those displayed by
prokaryotes.
The major goal of this RFA is to support research
focused on the mechanisms of action by which the
mammalian innate immune system responds to the
food and waterborne protozoa from the NIAID
Category B Priority Pathogens list. Studies utilizing
human cells or clinical samples are not required, but
are strongly encouraged. Appropriate areas of research
include, but are not limited to: 1) Characterization of
host cells involved in the innate immune response to
protozoa; 2) Identiﬁcation of novel pathogen-associ-
ated molecular pattern recognition receptors on host
cells; 3) Characterization of mediators of innate immu-
nity that are produced by host cells stimulated by pro-
tozoa; 4) Elucidation of the intracellular signaling
pathways in the mammalian innate immune cells that
are stimulated by protozoa; 5) Comparison of human
versus animal model molecular responses to protozoan
pathogens or their components; 6) Human or animal
model gene mutations or polymorphisms associated
with distinctive innate immune responses to protozoa.
This initiative will unite interdisciplinary teams
of researchers with expertise in innate immunity,
mucosal immunity, and protozoan microbiology to
stimulate scientiﬁcally sound, original research that
will advance the ﬁeld and encourage productive inter-
actions among Principal Investigators. In the long
term, these efforts will form a basis for the rational
design of pathogen- or class-speciﬁc immunotherapeu-
tics, as well as adjuvants that will enhance the future
development of vaccines against potential bioweapons.
In some cases, immunological mechanisms
relevant to biodefense are broadly applicable for
many pathogens and may be most efﬁciently stud-
ied using model systems. Immunological research
that is directed at protozoa other than those listed as
NIAID Category B Priority Pathogens is responsive
to this announcement if the research specifically
addresses a practical approach to inducing, control-
ling, or improving the effectiveness of the innate
immune response to NIAID Category B protozoan
infection. Applicants must justify how the proposed
research is applicable to immune responses against
the listed agents.
Note: This RFA will NOT support clinical
trials; applications requesting support for clinical
trials will be considered nonresponsive and will be
returned to the applicant without review. However,
utilization of human-derived material in studies is
considered responsive.
This funding opportunity will use the individ-
ual Research Project Grant (R01) and Exploratory/
Developmental Research Grant (R21 ) award mech-
anisms.
This funding opportunity uses just-in-time con-
cepts. It also uses the modular as well as the nonmodu-
lar budget formats (see http://grants.nih.gov/grants/
funding/modular/modular.htm). Specifically, if you
are submitting an application with direct costs in each
year of $250,000 or less, use the modular budget for-
mat described in the PHS 398 application instruc-
tions, available at http://grants.nih.gov/grants/funding/
phs398/phs398/398.html in an interactive format.
Otherwise, follow the instructions for nonmodular
research grant applications. For further assistance con-
tact GrantsInfo, 301-435-0714, (telecommunications
for the hearing impaired: TTY 301-451-0088) or by
e-mail: GrantsInfo@nih.gov.
Applications must be prepared using the most
current PHS 398 research grant application instruc-
tions and forms. Applications must have a D&B
Data Universal Numbering System (DUNS) number
as the universal identiﬁer when applying for Federal
grants or cooperative agreements. The D&B number
can be obtained by calling 866-705-5711 or through
the web site at http://www.dnb.com/us/. The D&B
number should be entered on line 11 of the face page
of the PHS 398 form.
The deadline for receipt of letters of intent is
October 24, 2005, with November 22, 2005 the
deadline for receipt of applications. The complete
version of this RFA is available at http://www.niaid.
nih.gov/ncn/budget/QA/fra-05-042.htm.
Contact: David B. Winter, Division of Allergy,
Immunology, and Transplantation, National Institute
of Allergy and Infectious Diseases, Room 3014,
MSC-6601, 6610 Rockledge Drive, Bethesda, MD
20892-6601 USA, (for express mail use 20817), 301-
496-7551, fax: 301-480-2381, e-mail: dwinter@
niaid.nih.gov. Reference RFA-AI-05-042